The Visual Pathway
Light travels through the eye and is processed through a remarkable series of transformations.
| Step | Process | Notes |
|---|
| 1. Cornea | Provides ~2/3 of focusing power | Fixed power; cannot adjust |
| 2. Aqueous humor | Clear fluid nourishing cornea and lens | Drainage issues cause glaucoma |
| 3. Pupil | Regulates light amount entering eye | Bright light = smaller pupil |
| 4. Lens | Provides ~1/3 of focusing power; adjusts for distance | Loses flexibility with age (presbyopia) |
| 5. Vitreous | Maintains eye shape | Liquefies with age |
| 6. Retina | Converts light to neural signals | Contains 100+ million photoreceptors |
| 7. Optic nerve | Carries signals to brain | 1.2 million nerve fibers |
| 8. Visual cortex | Processes signals into perception | Located in occipital lobe |
Photoreceptors: Rods and Cones
| Type | Number | Function | Location | Clinical Notes |
|---|
| Rods | ~120 million | Low-light (scotopic) vision | Peripheral retina | Responsible for night vision |
| Cones | ~6 million | Color and detail (photopic) vision | Concentrated in macula | Three types: red, green, blue |
Common Refractive Errors
Types of Vision Problems
| Condition | Cause | Vision Effect | Typical Onset |
|---|
| Myopia (nearsightedness) | Eye too long; light focuses in front of retina | Distant objects blurry | Childhood/adolescence |
| Hyperopia (farsightedness) | Eye too short; light focuses behind retina | Near objects blurry | Often present from birth |
| Astigmatism | Cornea or lens irregularly curved | Blurry at all distances | Can be present at birth or develop |
| Presbyopia | Lens loses flexibility | Near objects blurry | Age 40+ |
The Myopia Epidemic
Myopia has reached epidemic proportions globally, with profound implications for eye health.1
| Statistic | Finding |
|---|
| Current global prevalence | ~28% of population (2010)1 |
| Projected 2050 prevalence | ~50% of world population (4.8 billion)1 |
| High myopia 2050 projection | ~10% (938 million; increases serious eye disease risk)1 |
| Hunter-gatherer populations | Near-zero myopia prevalence |
| Risk per diopter increase | 40% higher risk of myopic maculopathy |
Outdoor Time and Myopia Prevention
Research consistently demonstrates that outdoor time prevents myopia development in children.2
| Outdoor Time (weekly) | Myopia Risk Reduction | Notes |
|---|
| 3.5 hours | Baseline | Insufficient protection |
| 7 hours | 20% reduced risk | ~1 hour daily |
| 16.3 hours | 53% reduced risk | ~2.3 hours daily |
| 27 hours | 69% reduced risk | ~4 hours daily |
Key research findings on outdoor time and myopia:2
- Each additional hour outdoors per day reduces myopia odds by approximately 13%
- Effect is strongest for children ages 5.5–8.5 years
- Outdoor time prevents myopia onset but does NOT slow progression once myopia has developed
- The protective factor appears to be bright light exposure, not exercise
Prevention vs. Progression
Outdoor time prevents myopia onset but does not slow progression in already-myopic children.2 Bright outdoor light (not exercise) is the protective factor. Earlier intervention (ages 3–8.5 years) is more effective than later.
Managing Myopia
| Intervention | Evidence | Notes |
|---|
| Outdoor time | Strong for prevention2 | 2+ hours daily recommended |
| Atropine eye drops (low-dose) | Moderate for slowing progression | 0.01–0.05% concentration |
| Orthokeratology (Ortho-K) | Moderate for slowing progression | Overnight corneal reshaping lenses |
| Multifocal contact lenses | Emerging evidence | May slow axial elongation |
| Limiting near work | Weak | 20-20-20 rule still reasonable |
Corrective Eye Surgery Options
Overview of Laser Vision Correction
Three main procedures reshape the cornea to correct refractive errors.
| Procedure | Method | Best For | Recovery |
|---|
| LASIK | Creates hinged flap; laser reshapes beneath | Fast recovery priority | 1–2 days |
| PRK | Removes surface epithelium; laser reshapes | Thin corneas, athletes, dry eye | Weeks to months |
| SMILE | Small incision; lenticule removed | Dry eye concerns, contact sports | Few days |
Detailed Comparison
| Factor | LASIK | PRK | SMILE |
|---|
| Flap creation | Yes | No | No |
| Visual recovery speed | Fastest | Slowest | Intermediate |
| Postoperative discomfort | Minimal | Several days significant | Minimal |
| Corneal nerve recovery | Slowest | Fastest | Intermediate |
| Biomechanical strength | Reduced (flap) | Preserved | Better than LASIK |
| Dry eye risk (long-term) | Higher | Lower | Lower |
| Enhancement ease | Easy | More difficult | More difficult |
| Flap complications | Possible | N/A | N/A |
| Corneal haze risk | Very low | Possible | Very low |
Candidacy Considerations
| Favors LASIK | Favors PRK | Favors SMILE |
|---|
| Need fastest recovery | Thin corneas | Dry eye tendency |
| Not in contact sports | Contact sports/military | Contact sports |
| No significant dry eye | Irregular corneas | Want flapless but quick recovery |
| Accept flap risks | Willing to wait for recovery | Moderate myopia |
Long-Term Outcomes3
Research with 10+ year follow-up demonstrates:
- >99% achieve 20/40 vision or better (legal driving threshold)
- ~95% achieve 20/20 or better
- >95% patient satisfaction rate (FDA PROWL studies)3
- Late complications are rare with all three procedures
- No clear superiority of one procedure over others for most patients
Important Considerations
| Factor | Explanation |
|---|
| Age | Best to wait until mid-20s when prescription stabilizes |
| Presbyopia | Surgery won’t prevent need for reading glasses after age 40 |
| Enhancement | Some patients need touch-up procedure |
| Dry eye | Most common side effect (usually temporary) |
| Night vision | Halos/glare possible, especially with larger pupils |
What Are Cataracts?
Cataracts involve clouding of the eye’s natural lens, occurring in virtually everyone who lives long enough.
| Feature | Description |
|---|
| Definition | Clouding/opacification of the crystalline lens |
| Prevalence at age 60 | ~40% have some degree of cataract |
| Prevalence at age 80 | >90% have visually significant cataracts |
| Risk factors | Age, UV exposure, diabetes, smoking, steroid use, trauma |
Types of Cataracts
| Type | Location | Symptoms | Risk Factors |
|---|
| Nuclear sclerotic | Center of lens | Gradual yellowing, near vision may temporarily improve | Aging |
| Cortical | Outer edges | Glare, contrast issues | Diabetes, UV exposure |
| Posterior subcapsular | Back surface | Glare, reading difficulty | Steroids, diabetes, UV |
Cataract Surgery
Modern cataract surgery is one of the most commonly performed and successful surgical procedures.
| Aspect | Information |
|---|
| Procedure | Phacoemulsification (ultrasound breaks up lens); artificial lens implanted |
| Duration | 15–30 minutes typically |
| Anesthesia | Usually topical (eye drops) |
| Recovery | Visual improvement within days; full healing 4–8 weeks |
| Success rate | >95% achieve improved vision |
Intraocular Lens Options
| Lens Type | Function | Best For | Considerations |
|---|
| Monofocal | Single focus distance | Those accepting glasses for some tasks | Covered by insurance; most predictable |
| Multifocal | Multiple focus zones | Those wanting glasses independence | More glare/halos possible |
| Extended depth of focus (EDOF) | Extended focus range | Intermediate/distance priority | Less halos than multifocal |
| Toric | Corrects astigmatism | Those with significant astigmatism | Can be combined with above |
Prevention Strategies
| Strategy | Evidence | Recommendation |
|---|
| UV protection (sunglasses) | Strong | Wear UV-blocking sunglasses outdoors |
| Not smoking | Strong | Smoking accelerates cataract formation |
| Blood sugar control | Moderate | Diabetes increases cataract risk |
| Antioxidants | Weak | Healthy diet reasonable but supplements unproven |
Understanding AMD
AMD affects the macula, the central retinal area responsible for sharp, detailed vision.
| Feature | Dry AMD | Wet AMD |
|---|
| Prevalence | 85–90% of AMD cases | 10–15% of cases |
| Mechanism | Drusen accumulation; RPE deterioration | Abnormal blood vessel growth |
| Progression | Usually gradual | Can be rapid |
| Vision loss pattern | Central vision affected | Sudden central vision changes |
| Treatment | AREDS2 supplements; monitoring | Anti-VEGF injections |
Risk Factors
| Risk Factor | Impact | Modifiability |
|---|
| Age | Primary risk factor; increases after 50 | Non-modifiable |
| Family history | 3–4× increased risk with affected parent/sibling | Non-modifiable |
| Smoking | 2–4× increased risk | Modifiable |
| Caucasian race | Higher risk than other ethnicities | Non-modifiable |
| UV exposure | Contributes to oxidative damage | Modifiable |
| Cardiovascular disease | Shared risk factors | Partially modifiable |
| Obesity | Associated with progression | Modifiable |
| Diet low in carotenoids | Lower macular pigment | Modifiable |
The AREDS2 Formula4
The landmark AREDS2 study established the benefit of specific supplements for slowing AMD progression.
| Component | Daily Amount | Notes |
|---|
| Vitamin C | 500 mg | Antioxidant |
| Vitamin E | 400 IU | Antioxidant |
| Zinc | 80 mg (as zinc oxide) | May reduce to 25 mg to avoid GI upset |
| Copper | 2 mg | Prevents zinc-induced deficiency |
| Lutein | 10 mg | Replaced beta-carotene in AREDS2 |
| Zeaxanthin | 2 mg | Macular pigment precursor |
Important Notes on AREDS2
Who benefits: Those with intermediate AMD or advanced AMD in one eye. Risk reduction is ~25% for progression to advanced AMD.4 The formula is NOT shown to prevent AMD in those without disease. Beta-carotene (original AREDS) increases lung cancer risk in smokers (OR 1.82)—use the AREDS2 formula with lutein/zeaxanthin instead, which is 15% more effective at 10 years.4
Lutein and Zeaxanthin: The Science
| Finding | Evidence |
|---|
| Macular pigment formation | Only dietary carotenoids that accumulate in macula |
| Mechanism | Filter blue light; neutralize reactive oxygen species |
| Effect on early AMD | Limited evidence for prevention |
| Effect on late AMD | May be protective4 |
| Geographic atrophy | Slows progression toward fovea (80 vs 114 μm/year) |
| Dietary sources | Dark leafy greens (kale, spinach), egg yolks |
Monitoring and Early Detection
| Self-Monitoring Tool | Description |
|---|
| Amsler Grid | Grid pattern to detect distortion; check each eye separately |
| Frequency | Weekly or as recommended by ophthalmologist |
| Action if changes | Contact ophthalmologist immediately if lines appear wavy |
Glaucoma: The Silent Vision Thief
What Is Glaucoma?
Glaucoma involves progressive damage to the optic nerve, typically associated with elevated intraocular pressure (IOP), leading to irreversible vision loss.
| Feature | Description |
|---|
| Global prevalence | ~80 million people worldwide |
| Vision loss pattern | Peripheral vision lost first; central vision preserved until late |
| Nickname | “Silent thief of sight” (no early symptoms) |
| Reversibility | Damage is permanent; treatment prevents further loss |
Types of Glaucoma
| Type | Mechanism | Onset | Notes |
|---|
| Primary open-angle | Gradual drainage reduction | Slow, progressive | Most common (90% of cases) |
| Angle-closure | Drainage angle physically blocked | Can be acute | Emergency if acute; more common in Asian populations |
| Normal-tension | Optic nerve damage despite normal IOP | Slow | Suggests pressure-independent mechanisms |
| Secondary | Due to other conditions | Variable | Trauma, inflammation, medications |
Risk Factors
| Risk Factor | Impact |
|---|
| Elevated IOP | Only modifiable risk factor currently |
| Age >60 | Significantly increased risk |
| African ancestry | 6–8× higher risk than Caucasians |
| Family history | 4–9× increased risk |
| Myopia (nearsightedness) | Increased risk |
| Thin corneas | Associated with higher true IOP |
| Diabetes | Possible increased risk |
| Corticosteroid use | Can elevate IOP |
Treatment Goals and Options
| Treatment | Mechanism | Notes |
|---|
| Eye drops (prostaglandins) | Increase fluid outflow | First-line; once daily |
| Beta-blocker drops | Reduce fluid production | Systemic effects possible |
| Laser trabeculoplasty | Improves drainage | Can reduce drop dependence |
| MIGS (minimally invasive surgery) | Enhances drainage | Often combined with cataract surgery |
| Trabeculectomy | Creates new drainage pathway | For advanced or uncontrolled cases |
| Tube shunts | Artificial drainage device | For refractory cases |
Target Pressure Reduction
| Glaucoma Severity | Target IOP Reduction |
|---|
| Mild | 20–25% from baseline |
| Moderate | 30–35% from baseline |
| Severe | >40% from baseline |
Screening Recommendations
| Organization | Recommendation |
|---|
| American Academy of Ophthalmology | Comprehensive exam at age 40 for all adults |
| Higher risk individuals | Earlier and more frequent screening |
| USPSTF | Insufficient evidence for universal screening (as of 2013) |
Dry Eye Disease
Understanding Dry Eye
Dry eye is a chronic, often inflammatory condition affecting approximately 14% of US adults.
| Component | Description |
|---|
| Tear film layers | Lipid (outer), aqueous (middle), mucin (inner) |
| Mechanisms | Decreased production OR increased evaporation |
| Prevalence | Higher in women; increases with age |
| Impact | Discomfort, visual disturbance, ocular surface damage |
Types and Causes
| Type | Mechanism | Common Causes |
|---|
| Aqueous deficient | Reduced tear production | Aging, autoimmune (Sjogren’s), medications |
| Evaporative | Tears evaporate too quickly | Meibomian gland dysfunction, environment, incomplete blink |
| Mixed | Both mechanisms | Common, especially in older adults |
Contributing Factors
| Factor | Mechanism |
|---|
| Screen time | Reduced blink rate (from 15–20/min to 4–5/min) |
| Air conditioning/heating | Low humidity increases evaporation |
| Contact lenses | Disrupt tear film; reduce corneal sensation |
| Medications | Antihistamines, antidepressants, beta-blockers |
| Autoimmune disease | Sjogren’s syndrome attacks tear glands |
| LASIK/refractive surgery | Corneal nerve disruption (usually temporary) |
| Aging | Decreased tear production |
| Hormonal changes | Menopause increases risk |
Treatment Ladder
| Level | Intervention | Evidence |
|---|
| 1. Environmental | Humidifiers, screen breaks, blink exercises | Reasonable; limited data |
| 2. Artificial tears | OTC lubricating drops | Safe; effective for symptom relief |
| 3. Warm compresses | Heat to meibomian glands | Improves lipid layer |
| 4. Lid hygiene | Clean eyelids; treat blepharitis | Standard of care |
| 5. Omega-3 supplements | Fish oil/flaxseed oil | No significant benefit vs placebo (DREAM study)5 |
| 6. Prescription drops | Cyclosporine (Restasis), Lifitegrast (Xiidra) | Reduce inflammation |
| 7. Punctal plugs | Block tear drainage | Increases tear retention |
| 8. Autologous serum tears | Made from patient’s blood | For severe cases |
Omega-3 Fatty Acids: The Evidence5
| Study | Finding |
|---|
| DREAM study (NEJM, 2018) | No significant benefit of omega-3 vs. placebo for dry eye symptoms5 |
| Study design | 535 patients, 3000mg EPA+DHA vs olive oil placebo, 12 months |
| Result | Both groups improved ~13 points on OSDI; no difference between groups5 |
| Meta-analyses | Mixed results; some show improved signs (tear break-up time) but not symptoms |
| Current recommendation | Cannot be definitively recommended; may be reasonable to try |
Sunglasses and Eye Protection
UV Protection Importance
| UV Type | Eye Effects | Notes |
|---|
| UVA | Penetrates deeper; contributes to cataract, AMD | Present throughout day |
| UVB | Surface damage; photokeratitis (“snow blindness”) | Peak at midday |
| Blue light | Possible retinal effects; sleep disruption | From sun and screens |
Selecting Sunglasses
| Feature | Recommendation | Why |
|---|
| UV protection | 100% UVA and UVB blocking | Essential; darkness without UV protection may be worse |
| Lens color | Gray (neutral), brown, green | Personal preference; doesn’t affect UV protection |
| Polarization | Reduces glare | Helpful for driving, water activities |
| Wraparound style | Blocks peripheral light | Better protection |
| Size | Larger frames | More coverage |
Beyond UV: Sunglasses Benefits
| Benefit | Mechanism |
|---|
| Cataract delay | UV contributes to lens protein damage |
| AMD protection | Reduces oxidative stress to retina |
| Pterygium prevention | UV causes this corneal growth |
| Skin cancer around eyes | 5–10% of skin cancers occur on eyelids |
| Squamous cell carcinoma of conjunctiva | UV exposure increases risk |
Screen Time and Eye Health
Digital Eye Strain
| Symptom | Cause |
|---|
| Eye fatigue | Prolonged focusing at fixed distance |
| Dry eyes | Reduced blink rate during screen use |
| Headaches | Eye strain, poor posture |
| Blurred vision | Focusing fatigue |
| Neck/shoulder pain | Poor ergonomics |
The 20-20-20 Rule
Every 20 minutes, look at something 20 feet away for 20 seconds.
| Intervention | Evidence | Recommendation |
|---|
| Frequent breaks | Good rationale | 20-20-20 rule |
| Artificial tears | Proven for dry eye symptoms | Use as needed |
| Proper lighting | Reduces contrast strain | Avoid screen brighter than room |
| Blue light glasses | Limited evidence for eye protection | May help sleep if used at night |
| Screen position | Reduces strain | Slightly below eye level; arm’s length |
Best Practices
| Practice | Importance | Reason |
|---|
| Hand washing before handling | Critical | Prevents infection |
| Replace as scheduled | High | Overworn lenses harbor bacteria |
| Never sleep in daily wear lenses | Critical | Increases infection risk 6–8× |
| Never use water | Critical | Acanthamoeba and other organisms |
| Replace case every 1–3 months | High | Cases harbor biofilm |
| Use fresh solution daily | Critical | Never “top off” old solution |
Warning Signs Requiring Immediate Attention
| Sign | Possible Cause |
|---|
| Red eye with pain | Infection (keratitis) |
| Sensitivity to light | Corneal involvement |
| Discharge | Infection |
| Blurred vision not corrected by removing lens | Corneal damage |
| Pain persisting after lens removal | Corneal abrasion or infection |
The Eye as a Window to Systemic Health
An eye exam can reveal signs of systemic disease, sometimes before other symptoms appear.
| Finding on Eye Exam | Possible Systemic Condition |
|---|
| Diabetic retinopathy | Diabetes mellitus |
| Hypertensive retinopathy | High blood pressure |
| Cholesterol deposits (arcus) | Hyperlipidemia |
| Optic nerve pallor | Multiple sclerosis, brain tumor |
| Roth spots | Endocarditis, leukemia |
| Copper-colored deposits (Kayser-Fleischer rings) | Wilson’s disease |
| Retinal emboli | Carotid artery disease, cardiac source |
| Cotton-wool spots | Diabetes, hypertension, HIV, lupus |
| Uveitis | Autoimmune disease, infection |
GLP-1 Medications and Eye Health
GLP-1 receptor agonists (such as semaglutide and liraglutide)—widely prescribed for type 2 diabetes and weight management—are generating significant interest for their potential effects on eye health. The research is evolving, but several key findings have emerged.
Potential Benefits: AMD Risk Reduction
A 2025 multicenter study published in JAMA Ophthalmology examined over 91,000 patients with obesity (but without diabetes) and found that GLP-1RA use was associated with a dramatically reduced risk of developing nonexudative age-related macular degeneration compared with other weight-loss drugs:8
- At 5 years: 84% reduced risk (RR 0.16)
- At 7 years: 87% reduced risk (RR 0.13)
- At 10 years: 91% reduced risk (RR 0.09)
The proposed mechanisms include GLP-1’s anti-inflammatory properties, improved metabolic health, and potential direct effects on retinal cells. However, this was an observational study, and randomized controlled trials are needed to confirm causation.
Diabetic Retinopathy: A Nuanced Picture
For patients with diabetes, the relationship between GLP-1RAs and diabetic retinopathy (DR) is more complex:
- The SUSTAIN-6 concern: The original semaglutide cardiovascular trial reported a higher rate of DR complications, raising early concern.
- Rapid glucose lowering: Much of the initial risk appears related to rapid improvements in blood sugar control—a phenomenon well-known with insulin therapy—rather than a direct drug effect.
- Large-scale meta-analysis (2025): A systematic review of 78 trials with over 73,000 participants found that semaglutide did not increase or decrease the overall risk of eye disorders or diabetic retinopathy (OR 1.04; 95% CI 0.92–1.17).9
- Preclinical promise: Laboratory studies suggest semaglutide may actually protect retinal blood vessels by reducing oxidative stress and improving vascular integrity.10
What This Means for Patients
Key Point: GLP-1 medications appear safe for the eyes overall and may offer significant protective benefits against age-related macular degeneration. Patients with diabetes starting GLP-1 therapy should have a baseline dilated eye exam and close monitoring during the first year, particularly if they have pre-existing retinopathy, as rapid blood sugar improvements can temporarily worsen DR regardless of the medication used.
At Highland Longevity, we incorporate eye health monitoring into our GLP-1 medication management protocols, ensuring patients receive appropriate screening before and during treatment.
Eye Exam Recommendations
Frequency Guidelines
| Age Group | Recommendation | Notes |
|---|
| Children | First exam by age 1, then at 3, before school | Detect amblyopia early |
| Adults 20–39 | Every 5–10 years if asymptomatic | More frequent if risk factors |
| Adults 40–54 | Every 2–4 years | Glaucoma risk increases |
| Adults 55–64 | Every 1–3 years | Cataract, AMD risk increases |
| Adults 65+ | Every 1–2 years | Multiple age-related conditions |
| Diabetics | Annually (dilated exam) | Regardless of age |
Key Studies & Data
| Finding | Result | Significance |
|---|
| Global myopia projection | 50% of world population by 2050 (vs 28% in 2010)1 | Epidemic scale; major public health challenge |
| Outdoor time and myopia | 13% risk reduction per additional hour daily2 | Practical, modifiable prevention factor |
| LASIK outcomes | >95% achieve 20/20; >99% achieve 20/403 | High efficacy; >95% patient satisfaction |
| AREDS2 and AMD progression | 25% reduced risk of progression to advanced AMD4 | Evidence-based supplementation for intermediate AMD |
| Lutein vs beta-carotene | 15% better protection; no lung cancer risk4 | Safer formulation; 10-year data supports switch |
| Omega-3 for dry eye | No significant benefit vs placebo (DREAM study)5 | Major trial contradicts prior assumptions |
Additional Considerations
Study Limitations
- Myopia projections (Holden et al.) are based on 2010 data extrapolated forward; actual trends may differ with interventions1
- Outdoor time meta-analyses include observational studies; confounding factors (socioeconomic status, near work) may influence results2
- LASIK outcome data includes selection bias (patients with favorable anatomy more likely to proceed)
- AREDS2 enrolled patients at high risk of progression; benefits may not apply to those with early AMD or no AMD4
- DREAM study used olive oil placebo which itself contains oleic acid with potential anti-inflammatory effects5
Conflicting Evidence
- Some observational studies suggested omega-3 benefits for dry eye, but DREAM RCT found no difference vs placebo5
- Outdoor time clearly prevents myopia onset but does NOT slow progression once established—a key distinction often missed2
- Blue light blocking glasses have minimal evidence for eye protection but may benefit sleep through circadian effects
- While AREDS2 formula slows AMD progression, it does not prevent AMD onset—important distinction for marketing claims
Individual Variation
- Myopia development has strong genetic component; outdoor time benefits vary by baseline risk
- LASIK outcomes depend on corneal thickness, pupil size, and refractive error magnitude
- AMD risk varies by genetics (CFH, ARMS2 variants); AREDS2 benefits may differ by genotype
- Dry eye has multiple etiologies; treatment response depends on underlying cause (aqueous vs evaporative)
- Asian populations have higher rates of angle-closure glaucoma; screening approaches differ
Safety Notes
- LASIK contraindicated in keratoconus, thin corneas, unstable prescriptions, autoimmune disease
- AREDS2 zinc dose (80mg) may cause GI upset; reduced dose (25mg) comparable efficacy
- Beta-carotene in original AREDS formula increased lung cancer risk in smokers (OR 1.82)4—use AREDS2 formula
- Contact lens wear increases keratitis risk 6–8× when sleeping in daily-wear lenses
- Acute angle-closure glaucoma is a medical emergency requiring immediate treatment
Evidence Gaps
- Long-term (20+ year) outcomes of modern LASIK procedures not yet available
- Optimal outdoor time duration and timing for myopia prevention not precisely established
- Whether myopia control interventions (atropine, ortho-K) provide long-term benefit in reducing complications unknown
- Genetic testing for AMD risk not yet validated for clinical decision-making
- Screen time’s long-term effects on children’s eye development remain uncertain
Recent Developments
- 2024 meta-analyses confirm myopia prevalence continues accelerating, particularly in East Asia
- Combination myopia control (atropine + ortho-K) showing promise in clinical trials
- Novel AMD treatments targeting complement pathway (pegcetacoplan) approved for geographic atrophy
- Gene therapy trials underway for inherited retinal diseases
- AI-based screening for diabetic retinopathy now FDA-approved; expanding access to care
References
- Holden BA, Fricke TR, Wilson DA, et al. (2016). Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology, 123(5), 1036–1042. DOI: 10.1016/j.ophtha.2016.01.006
- Xiong S, Sankaridurg P, Naduvilath T, et al. (2017). Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmologica, 95(6), 551–566. DOI: 10.1111/aos.13403
- FDA LASIK Quality of Life Collaboration Project. (2014–2017). Patient-Reported Outcomes With LASIK (PROWL) Studies. U.S. Food and Drug Administration.
- Chew EY, Clemons TE, Agrón E, et al. (2022). Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28. JAMA Ophthalmology, 140(7), 692–698. DOI: 10.1001/jamaophthalmol.2022.1640
- Dry Eye Assessment and Management Study Research Group. (2018). n-3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine, 378(18), 1681–1690. DOI: 10.1056/NEJMoa1709691
- American Academy of Ophthalmology. (2024). Preferred Practice Pattern: Comprehensive Adult Medical Eye Evaluation. AAO.
- Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. DOI: 10.1056/NEJMoa1607141
- Ahuja AS, Paredes AA 3rd, Young BK. (2025). Glucagon-like peptide-1 receptor agonists and age-related macular degeneration. JAMA Ophthalmology, 143(12), 999–1003. DOI: 10.1001/jamaophthalmol.2025.3821
- Natividade GR, Spiazzi BF, Baumgarten MW, et al. (2025). Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmology, 143(9), 759–768. DOI: 10.1001/jamaophthalmol.2025.2489
- Cheng X, Fu Z, Chen Y, et al. (2025). Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro. Diabetes, Obesity and Metabolism, 27(12), 7085–7096. DOI: 10.1111/dom.70107
Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health regimen. Individual results may vary. The information presented reflects current research as of March 2026 and may be updated as new evidence becomes available.